October 17th 2024
Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.
Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.
September 13th 2024
Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.
September 6th 2024
Grzegorz S. Nowakowski, MD, discusses the treatment landscape for DLBCL and the need for novel therapeutic approaches in the second-line setting.
September 4th 2024
Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.
July 17th 2024
Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
February 20th 2024
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
February 13th 2024
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
February 6th 2024
Experts on mantle cell lymphoma discuss second-line treatment options available for patients.
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
January 30th 2024
Experts on mantle cell lymphoma discuss first-line treatment options available for patients.
Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
January 23rd 2024
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
January 16th 2024
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
January 10th 2024
Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.